LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
15 hedge funds and large institutions have $11.7M invested in LAVA Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
4% more capital invested
Capital invested by funds: $11.2M → $11.7M (+$476K)
4.26% less ownership
Funds ownership: 26.12% → 21.86% (-4.3%)
21% less funds holding
Funds holding: 19 → 15 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
+$185K |
| 2 |
Millennium Management
New York
|
+$148K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$27.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22.1K |
| 5 |
HF
HRT Financial
New York
|
+$19.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.24M |
| 2 |
Axa
Paris,
France
|
-$375K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$233K |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$88.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$53.5K |
LVTX Hedge Fund Activity: Q2 2023 in Review
15 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2023, worth a combined $11.7M — up 4.3% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of LVTX and 5 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Bruce & Co, adding an estimated $185K. The largest seller was Novo Holdings A/S, cutting an estimated $1.24M.
- 15 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2023, down from 19 in Q1 2023.
- Funds reported $11.7M of LAVA Therapeutics stock for Q2 2023, up 4.3% quarter-over-quarter.
- 5 funds opened new LAVA Therapeutics positions in Q2 2023 and 9 closed out, a net change of -4 holders.
- The largest LAVA Therapeutics buyer in Q2 2023 was Bruce & Co, an estimated $185K added.
- The largest LAVA Therapeutics seller in Q2 2023 was Novo Holdings A/S, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2023.